A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component

Trial Profile

A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Afibrinogenaemia; Surgical blood loss
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 24 Aug 2017 Planned End Date changed from 1 Dec 2017 to 15 Dec 2017.
    • 24 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.
    • 21 Dec 2016 Planned number of patients changed from 20 to 23.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top